AstraZeneca inks $730m licensing deal for rare heart disease treatment

Alexion, AstraZeneca’s rare disease group, has entered into an exclusive licensing agreement with Neurimmune AG for NI006, an antibody in development for the treatment of the heart condition, transthyretin amyloid cardiomyopathy (ATTR-CM).

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Biotech

10x Genomics dealt major blow in sequencing fight

20 August 2026 Three disputed sequencing patents took the spotlight as the Federal Circuit weighed challenges to a trio of PTAB rulings.

Biotech

Europe’s missing biotech bridge: Why IP ownership matters more than capital access

17 August 2026 Europe’s biotechnology challenge is not only whether it can fund innovation. It is whether it can continue to originate and control the foundational IP positions from which future biotech value is created. Paul Calvo of Sterne Kessler explains.

Biotech

Masimo keeps $634m smartwatch award and moves to appeal

21 July 2026 Now a Danaher subsidiary, the company is contesting a number of orders after a California court finalised several aspects of the high-profile dispute.

More features

Paul, Weiss finds appellate ‘star’ to lead Supreme Court practice

The buyers' wishlist: What makes a life sciences deal stack up?

UK appoints ex-engineer as new intellectual property Minister

Stris & Maher opens new Dallas office with partner hires

Teva and Aurinia settle generics dispute over lupus drug, voclosporin

10x Genomics dealt major blow in sequencing fight

SK Biopharmaceuticals settles epilepsy generic dispute

Vanda revives challenge over braille-free label on generic sleep disorder drug

AstraZeneca inks $730m licensing deal for rare heart disease treatment

More on this story

Editor's picks

Editor's picks

More features